Genmab — Februar 2019

[peter12]

Genmab har vel informeret alt det de skal. De er jo ikke forpligtet til at sige hvad det sælger om 5 år. Den Børsen artikelMygind linker til, forklarer det vist meget godt

[StockBull]

Ja 2019 negativt peter men fra 2020 er TV vel selvfinanceret og giver lidt overskud forhaabentligt

[StockBull]

Sammen med OFA kan det vel blive 5 bn inden 2025

[StockBull]

Saa + 13 bn med dara

[E_L]

Am I correct that -the Lancet focus is on safety data, and further mentions that for the whole TV201 cOR=15.6%

[E_L]

-that then Professor de Bono explained to other press that cohorts of patients with bladder cancer and cervical cancer showed 27 % respectively 26.5 % response (Confirmed response?) –which is basically what we know from ESMO?

[Bulder]

From the full Lancet article: Although this trial was not designed or powered to
assess antitumour activity, we report encouraging
preliminary antitumour activity for tisotumab vedotin in
a broad population of patients with heavily pretreated,
locally advanced or metastatic (or both) cancers of the
bladder, cervix, endometrium, oesophagus, lung, and
ovary.

[Bulder]

More: Limitations of this phase 1–2 open-label study include a
small sample size in some tumour types and the absence
of overall survival as a prespecified endpoint.

[Bulder]

Several studies are underway,
including InnovaTV 207 and InnovaTV 204. InnovaTV 207
(NCT03485209) is an ongoing phase 2 study evaluating
the activity, safety, and tolerability of tisotumab vedotin
monotherapy administered every 3 weeks in patients
with relapsed, locally advanced or metastatic colorectal
cancer, squamous non-small-cell lung cancer, pancreatic
cancer, or squamous cell carcinoma of the head and
neck.

[Bulder]

Following on from the encouraging preliminary activity seen in the cervical cancer cohort in this
study, InnovaTV 204 (NCT03438396) is an ongoing
phase 2 study evaluating the activity, safety, and
tolerability of tisotumab vedotin monotherapy in patients
with recurrent or metastatic cervical cancer that had
progressed during or after treatment with standard firstline therapy.

[Bulder]

So the resonserates mentioned are not final, but must be confirmed in follow up studies.

[Bulder]

@ Pensionisten: Så det videre forløb er InnovaTV 204 og 207, som skal bekræfte data.

[E_L]

great, thanks @Bulder (- i only have the summary article so far)

[Bulder]

Maybe a little dangerous of de Bono to go to the press with these preliminary data. On the other hand, when a scientist does this he must be on safe ground.

[E_L]

the feeling I got was that, maybe, he (or his sponsors...?) felt more data should have been disclosed as the lancet did, so he opened up a bit more?

[Hamming]

Iovance er data i Cervical er heller ikke helt off.

[Hamming]

https://twitter.com/bradloncar/status/1093911168060669952

[Bulder]

Sjovt de lige rammer 27%

[peter12]

Man skal passe meget på når N=15

[peter12]

Og det samme gælder selvfølgelig Genmabs forsøg